Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › SUVEN

SUVEN

Suven Life Sciences Limited
Micro-capPharma ↗

What the six lenses say about SUVEN — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹377.1
2026-09-08
VWAP · 1Y anchor
₹259
+45.4% from VWAP
P/E · TTM
-31.5×
TTM EPS ₹-12.0
52-week range
94%
position low→high
RSI(14)
60
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How SUVEN’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD788›

The actual numbers

Price vs VWAP (1y)+45.4%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+48.7%
Price vs 50-EMA+12.8%
RSI(14)60
RS vs Nifty 500 · 3M+57.1%
RS vs sector · 3M+51.0%
52-week range94%
Volume vs 30d avg0.55×
Volume vs 60d avg0.34×
ATR(14) · volatility21.5
Bollinger width · vol contraction0.203
FundamentalD541›

The actual numbers

Return on equity (ROE)-46.9%
Operating margin-3462.5%
Net margin-3462.5%
Revenue growth · YoY+29.3%
Debt / equity0.03×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)-31.5×
TTM EPS₹-12.0
52-week range94%
CatalystD433›

The actual numbers

Earnings & momentum41
Capital actions8
Governance50

Every filing in the corporate-announcements panel below.

FlowD860›

The actual numbers

Promoter holding70.2%
Delivery · 30d avg37.6%
Up/down-day asymmetry0.2pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D7 + D8 ) ÷ 2 = 7.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
85
Conviction score 85/100 · avg-decile strength 7.5/10
Conviction score85/100›
TechnicalD7›
FundamentalD5›
ValuationD1›
CatalystD4›
FlowD8›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.3pp
-2.5pp
+22.2pp
+58.6pp
+176.6pp
+65.6pp
Nifty 500
Broad-market baseline
+0.2pp
-2.5pp
+21.1pp
+57.1pp
+170.8pp
+60.4pp
Sector
Own-sector index
—
—
+18.3pp
+51.0pp
+157.7pp
+39.6pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

SUVEN daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
377.15-0.85

Relative strength

RS vs baseline · rebased to 100

SUVEN ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
248.21+0.49

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)13212132
↳ change QoQ—+155.8%-37.4%-37.9%+100.0%-50.0%+200.0%-33.3%
EBITDA (₹cr)-27-48-38-44-51-80-103-51
EBITDA margin-2637.2%-1872.3%-2334.0%-4400.0%-2550.0%-8000.0%-3433.3%-2550.0%
PAT (₹cr)-28-50-39-44-52-77-102-46
↳ change QoQ—-77.0%+21.2%-12.5%-18.2%-48.1%-32.5%+54.9%
Net margin-2787.3%-1929.5%-2429.8%-4400.0%-2600.0%-7700.0%-3400.0%-2300.0%
EPS (₹)-1.29-2.27-1.79-2.01-2.36-3.40-4.48-1.73
D/E————————
YoY growth · Mar '26Revenue +100.0% YoYPAT -4.5% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 3 Sep '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Monitoring Agency Report
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 30 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 8 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    LOWgovernance
    Allotment of Securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 Jun '26
    LOWgovernance
    Allotment of Securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 17 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma